Liraglutide can reduce the proliferation of PASMCs by inhibiting cellular Drp1/nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) pathway and Atg-5/Atg-7/Beclin-1/LC3β-dependent pathway of autophagy in PAH. Here, ATG5 is linked to pulmonary arterial hypertension.